CoChat

Targeting PP2A in cancer: an underrated option

Open access
Sarais, Fabio, Krempien, Finja, Koehn, Caroline, Brewing, Lara, Classen, Carl Friedrich, Walter, Michael, Shokraie, Olia · 2025 · Journal of Experimental & Clinical Cancer Research

The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index; 8 of the 162 sources its claims cite were checked for support.

Abstract

Protein phosphatase 2A plays a central role in modulating multiple signaling pathways, including PI3K, EGFR, Myc, WNT, JAK/STAT, RAS/MAPK, and NF-κB, which are frequently dysregulated in cancer. Although PP2A is broadly considered a tumor suppressor due to its frequent functional loss in tumors, its biological role is highly context-dependent and varies across cancer types and stages. The activity of the heterotrimeric PP2A complex is tightly controlled by the precise assembly and composition of the scaffolding (A), catalytic (C), and variable regulatory (B) subunits, with the latter exhibiting tissue- and developmental stage-specific patterns, thus allowing PP2A to exert context-dependent effects on signaling networks. In many cancers, PP2A dysregulation arises from mutations in subunit genes, post-translational modifications, or disrupted expression, leading to impaired holoenzyme formation and loss of activity. PP2A dysfunctionality often promotes the aberrant activation of pathways, including mTOR, and the enhanced phosphorylation of own and downstream targets, such as S6 kinase, facilitating tumor growth and progression. In this review, we discuss the mechanisms of PP2A dysregulation in cancer and highlight PP2A restoration as a promising therapeutic approach.

Overview

CoChat Summary

## TL;DR

This review argues that PP2A is a context-dependent cancer target: it can act as a tumor suppressor in many settings, but some PP2A complexes or regulatory states can also support oncogenic signaling. It highlights PP2A modulators already in preclinical/clinical study and makes a special case for the brain-enriched subunit PPP2R2C/B55γ as a potential biomarker and therapeutic handle.

## Key findings

  • PP2A is described as a major serine/threonine phosphatase that dephosphorylates over 300 substrates and is involved in more than 90 distinct holoenzyme assembly combinations.
  • In glioma/GBM, restoration of PPP2R2C/B55γ inhibited colony formation and suppressed proliferation in both in vitro and in vivo models; B55γ overexpression also decreased S6 kinase (S6K) phosphorylation.
  • In mouse models, Aα mutations or loss of B′ subunits promoted tumors: E64D/+, del5-6/+, and del5-6/E64D mice showed an approximately 50% increased lung cancer rate after benzopyrene exposure versus wild-type mice; B56δ KO animals developed malignant lymphomas and up to 60% of the oldest mice developed HCC.
  • The review notes therapeutic candidates and reported effects including LB-100 potentiating CAR-T efficacy in GBM via mTORC1 activation, and DBK-061/DBK-1154 (as named in the text) reducing intracranial tumor growth and increasing survival in GBM mouse models.

## Methods

  • Narrative review/overview of the PP2A literature, with a historical section, structural summary, and disease-by-disease discussion across cancers and selected neurodevelopmental disorders.
  • Synthesizes published evidence from in vitro experiments, mouse knockout/knock-in models, preclinical studies, and clinical studies/trials; no new patient cohort or original experimental dataset is presented in the text provided.
  • Main analysis is qualitative and mechanistic, organizing findings around PP2A structure, dysregulation, therapeutic modulation, PPP2R2C/B55γ, splice variants, biomarkers, and tumor microenvironment effects.

## Limitations

  • The paper explicitly notes that the functional significance of B55γ/PPP2R2C, including its transcriptional variants and protein isoforms, is incompletely understood, and that there is little direct evidence linking specific PPP2R2C splice variants to treatment-resistant GBM or prostate cancer.
  • It states that specificity and delivery efficiency remain major obstacles when targeting splicing events or abnormal RNA species at the post-transcriptional level.
  • Evident from the text: this is a review, so conclusions depend on heterogeneous prior studies rather than a single standardized dataset, and many claims are context-dependent across cancer types and model systems.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13046-025-03560-y

Cites

287 of 287 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Timeline of key milestones in the discovery of PP2A as a tumor suppressor. This figure highlights the pivotal discoveries that have shaped the current understanding of PP2A’s role in cancer biology. Created using biorender.com
Fig. 1 Timeline of key milestones in the discovery of PP2A as a tumor suppressor. This figure highlights the pivotal discoveries that have shaped the current understanding of PP2A’s role in cancer biology. Created using biorender.comCC BY · PubMed Central
Fig. 2 Schematic representation of the PP2A holoenzyme complex and its subunits. The holoenzyme consists of three subunits: scaffolding subunit A (yellow), catalytic subunit C (pink), and regulatory subunit B (pink). The A subunit consists of 15 HEAT repeats with designated binding sites for the regulatory subunit B’ (HR2-HR8) and the C subunit (HR11-HR15), facilitating assembly and spatial organization. The C subunit features structural motifs, loops, and helix switches that contribute to conformational changes essential for enzymatic function. It also coordinates magnesium (Mg²⁺), which is critical for phosphatase activity. The B family shares a typical motif of six β-propeller (WD40) repeats, which is a sequence of 44–60 amino acids (aa), mediating cellular localization, and substrate recognition by providing a platform for protein–protein or protein–DNA interactions [39]. Created in https://www.ncbi.nlm.nih.gov/Structure/icn3d (Access on 23.04.2025)
Fig. 2 Schematic representation of the PP2A holoenzyme complex and its subunits. The holoenzyme consists of three subunits: scaffolding subunit A (yellow), catalytic subunit C (pink), and regulatory subunit B (pink). The A subunit consists of 15 HEAT repeats with designated binding sites for the regulatory subunit B’ (HR2-HR8) and the C subunit (HR11-HR15), facilitating assembly and spatial organization. The C subunit features structural motifs, loops, and helix switches that contribute to conformational changes essential for enzymatic function. It also coordinates magnesium (Mg²⁺), which is critical for phosphatase activity. The B family shares a typical motif of six β-propeller (WD40) repeats, which is a sequence of 44–60 amino acids (aa), mediating cellular localization, and substrate recognition by providing a platform for protein–protein or protein–DNA interactions [39]. Created in https://www.ncbi.nlm.nih.gov/Structure/icn3d (Access on 23.04.2025)CC BY · PubMed Central
Fig. 3 Common mechanisms contributing to PP2A dysregulation. This figure depicts the key regulatory factors that influence the structural integrity and enzymatic activity of PP2A. Genomic alterations, PTMs, endogenous inhibitors, and viral proteins can all affect the subunit composition, assembly, and function of the PP2A holoenzyme. Disruption of the PP2A assembly may result in reduced, insufficient, or complete loss of phosphatase activity, thereby perturbing downstream signaling pathways and ultimately leading to diseases. Created using biorender.com
Fig. 3 Common mechanisms contributing to PP2A dysregulation. This figure depicts the key regulatory factors that influence the structural integrity and enzymatic activity of PP2A. Genomic alterations, PTMs, endogenous inhibitors, and viral proteins can all affect the subunit composition, assembly, and function of the PP2A holoenzyme. Disruption of the PP2A assembly may result in reduced, insufficient, or complete loss of phosphatase activity, thereby perturbing downstream signaling pathways and ultimately leading to diseases. Created using biorender.comCC BY · PubMed Central
Fig. 4 Signaling networks of PP2A. PP2A is a key regulator of cellular processes, including protein synthesis, cell cycle progression, proliferation, differentiation, and apoptosis. It modulates β-catenin stability in the Wnt pathway, controlling cell proliferation. PP2A balances the signals, determining the cell fate for proliferation or differentiation by fine-tuning phosphorylation. It also maintains proper cell cycle progression by regulating G1/S cyclins and ensuring cell survival by modulating mitogenic signals. Loss of PP2A function leads to apoptosis resistance by hyperactivating survival pathways, particularly the MAPK/ERK and PI3K/AKT cascades. Normally, PP2A counterbalances these pathways to maintain cellular homeostasis and prevent aberrant cell survival. As a central node in multiple signaling networks, PP2A dysfunction contributes to pathological conditions, such as cancer and neurodegeneration. Created using biorender.com
Fig. 4 Signaling networks of PP2A. PP2A is a key regulator of cellular processes, including protein synthesis, cell cycle progression, proliferation, differentiation, and apoptosis. It modulates β-catenin stability in the Wnt pathway, controlling cell proliferation. PP2A balances the signals, determining the cell fate for proliferation or differentiation by fine-tuning phosphorylation. It also maintains proper cell cycle progression by regulating G1/S cyclins and ensuring cell survival by modulating mitogenic signals. Loss of PP2A function leads to apoptosis resistance by hyperactivating survival pathways, particularly the MAPK/ERK and PI3K/AKT cascades. Normally, PP2A counterbalances these pathways to maintain cellular homeostasis and prevent aberrant cell survival. As a central node in multiple signaling networks, PP2A dysfunction contributes to pathological conditions, such as cancer and neurodegeneration. Created using biorender.comCC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 0 Not valid · 98 Not checked · 13 Own results and interpretations

44 more claims

Create a free account to see all 118 claims and to verify the 154 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 57

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 287 references

Cited by

See all 9

Metadata

Authors
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O.
Affiliations
Universitätsmedizin Rostock (DE)
Corresponding author
Shokraie, Olia
Venue
Journal of Experimental & Clinical Cancer Research
Published
2025-10-27
Volume
44
Issue
1
Pages
295-295
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W4415571081
Cited by
8
References
287
Citations by year
2026: 8
FWCI
0.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Universitätsmedizin Rostock
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
protein phosphatase 2A, PI3K signaling, mTOR signaling, tumor suppressor function, signaling pathway dysregulation
MeSH terms
Animals, Humans, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Protein Phosphatase 2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting PP2A in cancer: an underrated option. https://app.cochat.ai/papers/10.1186/s13046-025-03560-y
The paper
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025). Targeting PP2A in cancer: an underrated option. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03560-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.